Understanding Lymph Node Metastasis in Esophageal Cancer
The TIGER Study is an international multicenter prospective registry designed to systematically map lymph node metastasis patterns in esophageal and gastroesophageal junction cancer, informing evidence-based surgical practice worldwide.
Study Description
Esophageal cancer remains one of the most lethal malignancies worldwide, with lymph node involvement being one of the strongest prognostic factors. Despite decades of surgical experience, the optimal extent of lymphadenectomy remains debated, largely due to the heterogeneity of available data.
The TIGER Study addresses this gap by prospectively collecting detailed data on lymph node dissection from high-volume esophageal surgery centers globally. Each participating institution records the anatomical station, total nodes harvested, and metastatic involvement for every patient undergoing esophagectomy, alongside comprehensive clinical, pathological, and outcome data.
By aggregating data from diverse surgical practices and patient populations, the TIGER Study generates the statistical power needed to define metastatic patterns and evaluate the impact of lymphadenectomy extent on oncological outcomes with unprecedented granularity.
Study Objectives
The TIGER Study is designed around clearly defined objectives that address critical gaps in surgical oncology evidence.
Primary Objective
Map the prevalence and distribution of lymph node metastasis by anatomical station in esophageal and gastroesophageal junction cancer, stratified by tumor location, histological type, and clinical stage.
Pathological Analysis
Establish standardized reporting of lymph node yield and metastatic involvement across participating centers, enabling quality benchmarking and protocol harmonization.
Outcome Evaluation
Evaluate the association between extent of lymphadenectomy, lymph node yield, and long-term oncological outcomes including overall survival, disease-free survival, and recurrence patterns.
Guideline Development
Generate evidence to inform clinical guidelines on optimal lymphadenectomy extent based on tumor characteristics, contributing to precision surgical oncology.
Study Endpoints
Primary Endpoints
- Prevalence and distribution of lymph node metastasis by anatomical station
- Lymph node metastasis patterns stratified by tumor location (upper, middle, lower third, GEJ)
- Metastatic involvement by histological type (adenocarcinoma vs. squamous cell carcinoma)
- Correlation between clinical/pathological staging and lymph node status
Secondary Endpoints
- Overall survival at 1, 3, and 5 years by lymphadenectomy extent
- Disease-free survival and recurrence patterns
- Postoperative morbidity and 30/90-day mortality rates
- Lymph node yield as a quality indicator across institutions
- Impact of neoadjuvant therapy on lymph node metastasis patterns
Study Leadership
The TIGER Study is governed by an international steering committee coordinated by Amsterdam UMC.
Study Steering Committee
Principal Investigators
Amsterdam UMC
Regional Coordinators
Continental Study Leads
Europe, Asia-Pacific, Americas
Statistical Core
Biostatistics & Data Management
Independent Statistical Unit
Study Timeline
TIGER Study concept developed at Amsterdam UMC. Initial protocol design and ethics framework established.
Multicenter study protocol finalized with input from 30+ expert centers. IRB approvals obtained at founding institutions.
First wave of institutions in Europe and Asia-Pacific begin patient enrollment. Electronic data capture system deployed.
Study network expands to dozens of institutions across multiple continents. Thousands of patients enrolled.
Initial results published in high-impact surgical journals. Landmark findings on lymph node metastasis patterns disseminated.
Growing network of institutions actively contributing. Digital platform with real-time analytics and benchmarking capabilities launched.
Methodology
Study Design
International multicenter prospective registry study
Eligibility Criteria
Consecutive patients undergoing esophagectomy with curative intent for esophageal or gastroesophageal junction cancer at participating institutions.
Data Collection
Standardized electronic case report forms (eCRF) capturing demographics, tumor characteristics, operative details including lymph node station mapping, pathological assessment, and follow-up outcomes at 30 days, 90 days, and annually.
Quality Assurance
Built-in data validation rules, periodic source data verification at selected sites, and centralized statistical monitoring for consistency and completeness.